ID | 1151 |
Name of the vaccine | PedvaxHib |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 2 to 71 months |
Description of the vaccine | Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PRP-OMPC). |
Name of the manufacturer | Merck and Co. , INC. |
Name of the manufacturing country | United States |
Year of manufacture | 1989 |
Clinical Phase status | Approved |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | 93% for primary two doses. Efficacy for follow up period - 96.6% in children under 18 months and 100% in children over 18 months of age. |
Vaccine formulation | Liquid |
Dosage | Infants (2 to 14 months) : 0.5 mL dose at 2 months and a dose 2 months later. A booster dose (0.5 mL) at 12 to 15 months.
Children (15 months and older) : single 0.5 mL dose. |
Mechanism of action | From 0.15 to 1.0 mcg/mL. |
Route of administration | Intramuscular |
Indications | Routine vaccination against invasive disease caused by Haemophilus influenzae type b. |
Export | Distributed by - Merck and Co. , INC. |
Approval | NA |
Adjuvant | NA |
Repurposing | For Meningococcal disease. |
Side effects of vaccine | Irritability, sleepiness, injection site pain, erythema, swelling, unusual high pitched crying, prolonged crying, diarrhoea, vomiting, otitis media, rash, and upper respiratory infection. |
Post vaccination | NA |
Dose type | Both |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/80438/download |
Other name | NA |
Additional Links | NA
|